 |
7 Products |  |
14 Diseases | | 7 Products |
|
0 Trials |  |
38 News |  |
- alhydrogel injectable (AD04) / ADvantage Therap, ondansetron ultra-low dose (AD04) / Adial
AD04 (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1436;
Based on these preclinical results we conclude that AD04 administration induces microglia to phagocytose brain debris, such as apoptotic neurons, synapses and degraded myelin in the aged brain, and in the AD brain also Abeta, extracellular tau tangles and oxidized lipids. By changing the microglial phenotype, AD04, indirectly reduces the neuroinflammation induced by Abeta, tau and neuronal debris, leading to an anti-inflammatory milieu in the brain which protects and rescues the hippocampus from neurodegeneration.
- | C6-17 / AFFiRiS
Preclinical, Journal, IO biomarker: Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. (Pubmed Central) - Jan 8, 2024
Compared to CTRL mAB or vehicle treated mice, the mAB C6-17 treated YAC128 animals showed improved body weight and motor behaviors, a delayed progression in motor deficits and reduced striatal EM48 immunoreactivity. These results provide the first proof of concept for the feasibility and therapeutic efficacy of an antibody-based anti-HTT passive immunization approach and suggest this modality as a potential new HD treatment strategy.
- Time saved in disease progression for treatments in AD (including 3 monoclonal antibodies and 2 other promising treatments) (Hall 12 (RAI Amsterdam Convention Centre)) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3833;
Progressive diseases would cease to be diseases at all if there was no progression of symptoms. Focusing on the clinical meaningfulness of each separate point on each outcome distracts us from this overall goal.
- || PD03A / AFFiRiS
Clinical, P1 data, Journal: Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. (Pubmed Central) - Jan 20, 2022
Focusing on the clinical meaningfulness of each separate point on each outcome distracts us from this overall goal. The safety profile and positive antibody response of PD03A supports the further development of active immunotherapeutic approaches for the treatment of PD.
- || Affitope AT06A + adjuvant / AFFiRiS, Affitope AT04A + adjuvant / AFFiRiS
Clinical, P1 data, Journal: A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. (Pubmed Central) - Jan 11, 2022
P1
The safety profile and positive antibody response of PD03A supports the further development of active immunotherapeutic approaches for the treatment of PD. Although both AT04A and AT06 were safe and immunogenic, only AT04A demonstrated significant LDLc-lowering activity, justifying further development.
- || C6-17 / AFFiRiS
Review, Journal: Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. (Pubmed Central) - Jul 16, 2021
Immunohistochemical stainings of post-mortem HD brain tissue confirmed the specificity of mAB C6-17 to human mutHTT aggregates. These findings demonstrate that mAB C6-17 not only successfully engages with its target, mutHTT, but also inhibits cell uptake suggesting that this antibody could interfere with the pathological processes of mutHTT spreading in vivo.
- [VIRTUAL] Experimental Therapies for Rare Movement Disorders – MSA (Room Vienna) - May 30, 2021 - Abstract #EAN2021EAN_1278;
P1, P2
In this regard, enhancing the clearance of α-synuclein via autophagy (transcription factor EB) or direct proteolysis (neurosin), inhibiting its aggregation (anle 138b and CLR01) or post-translational truncation (belnacasan), as well as active (Affitope PD01A) and passive immunotherapy (CD5-D5) have demonstrated beneficial effects on motor behavior, α-synuclein burden and other neuropathological readouts in transgenic MSA mice...These preclinical results have motivated the conduction of a phase I trial to evaluate the safety and tolerability of repeated administrations of specific active immunotherapy against α-synuclein with Affitope PD01A and PD03A (NCT02270489)...In this regard, a phase I trial to assess the safety and tolerability of anle138b in healthy volunteers is currently ongoing (NCT04208152). Additionally, a small phase II trial with exenatide (NCT04431713), an approved antidiabetic, is ongoing.
- || Affitope PD01A / AFFiRiS, PD03A / AFFiRiS
Clinical, P1 data, Journal: A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. (Pubmed Central) - Apr 28, 2021
P1
Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.
- cinpanemab (BIIB054) / Biogen, prasinezumab (RG7935) / Roche, PD03A / AFFiRiS
[VIRTUAL] ACTIVE AND PASSIVE IMMUNIZATION IN THE TREATMENT OF PARKINSON’S DISEASE (On Demand Symposia A) - Dec 24, 2020 - Abstract #ADPD2021ADPD_222;
To obtain active immunization AFFITOPE PD01A/PD03A has been tested in patients and healthy controls...Passsive immunization has been tested using two human antibodies PRX002/RG7935, and BIIB054...BIIB054 is actually in phase IIb since 18 months, no significant side effects have been reported during the double blind phase and interim results on clinical end-points are expected. Two other studies are starting one with UCB compound and another study with PRX.
- || PD03A / AFFiRiS
MSA Pipeline Continued. CoQ10 trial in Japan 🇯🇵 Intranasal insulin PD01A /PD03A Sympath - vaccine for MSA to impact AlphaSyn aggregates - phase 1 positive, Phase 2 pending https://t.co/R41gkmVbCm https://t.co/ugOB9sGxBz https://t.co/L6Htv3578B (Twitter) - Sep 22, 2019
- ||| AT04 / AFFiRiS
Trial completion: AFF012: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (clinicaltrials.gov) - Oct 20, 2017
P1, N=72, Completed, Sponsor: Affiris AG
Two other studies are starting one with UCB compound and another study with PRX. Active, not recruiting --> Completed
- | ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Trial completion: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Jun 5, 2017
P1, N=30, Completed, Sponsor: Affiris AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | PD03A / AFFiRiS
Trial completion: AFF011: Study Assessing Tolerability and Safety of AFFITOPE (clinicaltrials.gov) - Oct 31, 2016
P1, N=36, Completed, Sponsor: Affiris AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- PD03A / AFFiRiS
Trial primary completion date: AFF011: Study Assessing Tolerability and Safety of AFFITOPE (clinicaltrials.gov) - May 31, 2016
P1, N=36, Active, not recruiting, Sponsor: Affiris AG
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Aug 2016
- ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Enrollment closed, Trial primary completion date: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - May 31, 2016
P1, N=30, Active, not recruiting, Sponsor: Affiris AG
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2017
- || AT04 / AFFiRiS
Enrollment closed: AFF012: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (clinicaltrials.gov) - Feb 4, 2016
P1, N=72, Active, not recruiting, Sponsor: Affiris AG
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2017 Recruiting --> Active, not recruiting
- PD03A / AFFiRiS
Enrollment closed: AFF011: Study Assessing Tolerability and Safety of AFFITOPE (clinicaltrials.gov) - Aug 17, 2015
P1, N=36, Active, not recruiting, Sponsor: Affiris AG
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| AT04 / AFFiRiS
New P1 trial: AFF012: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (clinicaltrials.gov) - Jul 27, 2015
P1, N=72, Recruiting, Sponsor: Affiris AG
- ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Enrollment open: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Dec 19, 2014
P1, N=30, Recruiting, Sponsor: Affiris AG
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- PD03A / AFFiRiS
Enrollment open: AFF011: Study Assessing Tolerability and Safety of AFFITOPE (clinicaltrials.gov) - Nov 20, 2014
P1, N=36, Recruiting, Sponsor: Affiris AG
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ACI-7104.056 / AC Immune, PD03A / AFFiRiS
New P1 trial: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Oct 22, 2014
P1, N=30, Not yet recruiting, Sponsor: Affiris AG
- | PD03A / AFFiRiS
New P1 trial: AFF011: Study Assessing Tolerability and Safety of AFFITOPE (clinicaltrials.gov) - Oct 17, 2014
P1, N=36, Not yet recruiting, Sponsor: Affiris AG
- Affitope AD02 / AFFiRiS
Trial termination: Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=11, Terminated, Sponsor: Affiris AG
Not yet recruiting --> Recruiting Enrolling by invitation --> Terminated; The Study could not be done for every potential participant as planned in the protocol for organizational reasons.
- Affitope AD02 / AFFiRiS
Enrollment change: Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=11, Terminated, Sponsor: Affiris AG
Enrolling by invitation --> Terminated; The Study could not be done for every potential participant as planned in the protocol for organizational reasons. N=20 --> 11
- |||| Affitope AD02 / AFFiRiS
Trial completion, IO biomarker: Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P2, N=335, Completed, Sponsor: Affiris AG
N=20 --> 11 Active, not recruiting --> Completed
- AD03 / AFFiRiS
Trial termination: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A (clinicaltrials.gov) - Nov 4, 2013
P=N/A, N=16, Terminated, Sponsor: Affiris AG
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; The study could not be performed as planned for organizational reasons.
- AD03 / AFFiRiS
Enrollment change: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A (clinicaltrials.gov) - Nov 4, 2013
P=N/A, N=16, Terminated, Sponsor: Affiris AG
Enrolling by invitation --> Terminated; The study could not be performed as planned for organizational reasons. N=24 --> 16
- | ATH03 / AFFiRiS
Trial completion: Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) (clinicaltrials.gov) - Jul 11, 2012
P1, N=36, Completed, Sponsor: Affiris AG
N=24 --> 16 Active, not recruiting --> Completed
- | AD03 / AFFiRiS
Trial completion: MimoVax: Safety and Tolerability of AFFITOPE AD03 (clinicaltrials.gov) - Dec 18, 2011
P1, N=28, Completed, Sponsor: Affiris AG
Active, not recruiting --> Completed Recruiting --> Completed